Although gastrointestinal stromal tumors (GISTs) are a rare type of cancer, they are the
commonest sarcoma in the gastrointestinal tract. Molecularly targeted therapy, such as …

Deregulated protein tyrosine kinase activity is central to the pathogenesis of human cancers.
Targeted therapy in the form of selective tyrosine kinase inhibitors (TKIs) has transformed …

Highlights•This clinical practice guideline provides key recommendations on the
management of gastrointestinal stromal tumours.•Recommendations have been agreed …

Gastrointestinal stromal tumours (GISTs) are rare tumours, with an estimated unadjusted
incidence of around 1/100 000/year [1]. This only covers clinically relevant GISTs, since, if …

Background Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal
tumors of the gastrointestinal tract. Neoplastic GIST cells seem to arise from a common …

Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment
and follow-up Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis …

Background No effective therapeutic options for patients with unresectable imatinib-resistant
gastrointestinal stromal tumour are available. We did a randomised, double-blind, placebo …

Background Gastrointestinal stromal tumour is the most common sarcoma of the intestinal
tract. Imatinib mesylate is a small molecule that inhibits activation of the KIT and platelet …

Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that
occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic …

Purpose The outcome of patients diagnosed with advanced gastrointestinal stromal tumor
(GIST) and treated long-term with imatinib mesylate is unknown. A previous report of a …